12:00 AM
Apr 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bydureon exenatide once weekly: Phase III started

Amylin began the open-label, international Phase III DURATION-6 trial to compare Bydureon exenatide once weekly vs. once-daily Victoza liraglutide in 900 patients. Amylin and Eli Lilly co-developed Bydureon, which uses drug delivery technology from Alkermes.

Last month, FDA issued a complete...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >